Literature DB >> 31116916

Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.

Jean Kim1, Tiffany Farchione1, Andrew Potter1, Qi Chen1, Robert Temple1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31116916     DOI： 10.1056/NEJMp1903305

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

Review 1.  Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.

Authors:  Jason Ng; Leanna M W Lui; Joshua D Rosenblat; Kayla M Teopiz; Orly Lipsitz; Danielle S Cha; Jiaqi Xiong; Flora Nasri; Yena Lee; Kevin Kratiuk; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Roger Ho; Bing Cao; Roger S McIntyre
Journal:  Psychopharmacology (Berl)       Date:  2021-01-23       Impact factor: 4.530

2.  Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor.

Authors:  Alessandra Grossert; Narges Zare Mehrjardi; Sarah J Bailey; Mark A Lindsay; Jürgen Hescheler; Tomo Šarić; Nicole Teusch
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

3.  The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.

Authors:  Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko
Journal:  Neuropharmacology       Date:  2019-05-31       Impact factor: 5.250

Review 4.  Neocortical circuits in pain and pain relief.

Authors:  Linette Liqi Tan; Rohini Kuner
Journal:  Nat Rev Neurosci       Date:  2021-06-14       Impact factor: 34.870

5.  Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm.

Authors:  Hector J Caruncho; Lisa E Kalynchuk; Kyle J Brymer; Jenessa Johnston; Justin J Botterill; Raquel Romay-Tallon; Milann A Mitchell; Josh Allen; Graziano Pinna
Journal:  Neuropsychopharmacology       Date:  2020-01-11       Impact factor: 7.853

6.  Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.

Authors:  Eric L Ross; Djøra I Soeteman
Journal:  Psychiatr Serv       Date:  2020-07-07       Impact factor: 3.084

7.  Development of the Ketamine Side Effect Tool (KSET).

Authors:  Brooke Short; Vanessa Dong; Verònica Gálvez; Vedran Vulovic; Donel Martin; Adam J Bayes; Carlos A Zarate; James W Murrough; Declan M McLoughlin; Patricio Riva-Posse; Robert Schoevers; Renerio Fraguas; Paul Glue; Johnson Fam; Rupert McShane; Colleen K Loo
Journal:  J Affect Disord       Date:  2020-01-25       Impact factor: 4.839

8.  Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.

Authors:  Keith A Trujillo; Colleen Y Heller
Journal:  Behav Brain Res       Date:  2019-10-05       Impact factor: 3.332

9.  Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review.

Authors:  Paul Glue; Bruce Russell; Natalie J Medlicott
Journal:  Eur J Clin Pharmacol       Date:  2020-11-18       Impact factor: 2.953

10.  Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic.

Authors:  Robert E Litman; Peter Sorantin; Elia E Acevedo-Diaz
Journal:  Innov Clin Neurosci       Date:  2021-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.